A Surrogate Measure for Time-Varying Biomarkers in Randomized Clinical Trials
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers developed a new statistical method to evaluate surrogate markers in clinical trials. This approach helps identify reliable markers for rare or distant outcomes, improving study efficiency.
Area Of Science
- Biostatistics
- Clinical Trial Design
- Epidemiology
Background
- Clinical trials with rare or distant outcomes necessitate large sample sizes and long durations, posing significant resource and time challenges.
- The use of surrogate markers is motivated by their potential for earlier and easier collection compared to traditional endpoints.
- Evaluating and ranking potential surrogate markers presents statistical complexities.
Purpose Of The Study
- To define a generalized proportion of treatment effect for survival settings that does not rely on model assumptions.
- To introduce a non-parametric estimator for this measure that is consistent and asymptotically normal.
- To provide a method for assessing the proportion of treatment effect mediated by a surrogate marker.
Main Methods
- Definition of a generalized proportion of treatment effect in survival analysis.
- Development of a non-parametric estimation procedure for the defined measure.
- Theoretical analysis of the estimator's properties, including consistency and asymptotic normality.
Main Results
- The proposed measure quantifies the proportion of average treatment effect mediated by a surrogate marker.
- The non-parametric estimator is shown to be consistent and asymptotically normal under specified conditions.
- The method is applicable to survival data without requiring specific model assumptions.
Conclusions
- The generalized proportion of treatment effect offers a model-free approach to evaluate surrogate markers in survival settings.
- The developed non-parametric estimator provides a statistically sound method for assessing marker utility.
- This work contributes to more efficient and feasible clinical trial designs by leveraging reliable surrogate markers.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...